Regeneron Pharmaceuticals announced Monday it plans to purchase human genetics and biotechnology firm 23andMe from bankruptcy ...

Regeneron announced a plan to acquire genetic testing firm 23andMe through bankruptcy court, including access to personal genetic data. What to know ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March, 23andMe said ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Tarrytown-based Regeneron would acquire 23andMe for $256 million under the deal that is pending approval by bankruptcy court and regulators. New York-based biotech giant Regeneron Pharmaceuticals ...

DNA testing company 23andMe (MEHCQ) is being purchased out of bankruptcy by large-cap drugmaker Regeneron (REGN), for $256 million. The deal includes "substantially all assets," but excludes the ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has been named the successful bidder in the bankruptcy auction for substantially all of the assets of ...